Par Drugs & Chemicals Ltd

As of November 17, 2025, Par Drugs & Chemicals is fairly valued with a PE ratio of 11.95 and an EV to EBIT of 8.99, significantly lower than its expensive peers, but has underperformed the Sensex with a stock return of -65.29%.

Par Drugs & Che. has shown consistent growth in net sales and profits, with net sales increasing from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25, and profit after tax reaching 13.36 Cr in Mar'25. Despite rising costs and cash flow challenges, the company maintains a healthy profit margin of 13.23%.

As of 07-Nov, Par Drugs & Chemicals Ltd's stock price is declining at 98.73, down 0.45% and significantly underperforming its sector. The company has reported negative results for three consecutive quarters, contributing to a 50.36% year-to-date decline, despite a low debt-to-equity ratio and modest sales growth.

As of 26-Sep, Par Drugs & Chemicals Ltd's stock price is at 104.06, down 4.07%, and has significantly underperformed its sector and the broader market. The company has faced declining profits over the past three quarters and shows weak long-term growth prospects, contributing to a year-to-date stock decline of 47.68%.

As of 24-Sep, Par Drugs & Chemicals Ltd is currently priced at 110.95, reflecting a 1.72% increase. Despite a significant 53.05% decline over the past year, the stock shows short-term resilience and an attractive valuation, outperforming its sector by 2.21%.

As of 23-Sep, Par Drugs & Chemicals Ltd's stock price is 109.07, down 2.98%, and has significantly underperformed its sector and the broader market. The company faces ongoing challenges with negative quarterly results and a year-to-date decline of 45.16%, indicating poor long-term growth prospects despite some favorable valuation metrics.

As of 22-Sep, Par Drugs & Chemicals Ltd's stock price is 112.42, down 0.22%, despite recent short-term gains of 6.29% and 13.87% over the past week and month. However, the stock has significantly underperformed over the year with a decline of 53.87%, raising concerns about its long-term growth outlook due to negative quarterly results and falling profits.

As of 19-Sep, Par Drugs & Chemicals Ltd's stock price is at 112.67, down 4.97%, and has underperformed its sector. Despite a recent positive return of 3.71% over the past week, the stock has declined 51.86% over the past year, indicating waning investor confidence amid poor long-term growth and negative quarterly results.

Par Drugs & Chemicals Ltd, a microcap in the Chemicals & Petrochemicals sector, faced notable trading activity as its stock reached the lower circuit limit. The stock's performance was below the sector average, with mixed trends in moving averages and a significant decline in its 1-day return.

As of 18-Sep, Par Drugs & Chemicals Ltd is currently priced at 118.56, having risen 1.68% today and outperforming the Sensex over the past week with a 4.39% gain. However, the stock has a significant year-to-date decline of 40.39% and a one-year decline of 50.36%, indicating ongoing long-term challenges.

Par Drugs & Chemicals Ltd, a microcap in the Chemicals & Petrochemicals sector, reached its upper circuit limit today, reflecting strong trading activity. The stock outperformed its sector and demonstrated robust liquidity, with significant trading volume and turnover, while maintaining a position above several moving averages.

Par Drugs & Chemicals Ltd is experiencing notable buying activity, with significant gains over the past week and month, outperforming the Sensex. Despite a decline over the past year, the stock has shown strong long-term growth. Today's trading session opened positively, maintaining upward momentum throughout the day.

As of 17-Sep, Par Drugs & Chemicals Ltd is seeing a price increase to 116.60, up 5.0%, and has outperformed its sector today. Despite a significant annual decline, recent positive returns suggest potential recovery, though long-term growth prospects remain uncertain due to stagnant sales and declining profits.

Par Drugs & Chemicals Ltd, a microcap in the Chemicals & Petrochemicals sector, reached its upper circuit limit today, trading at 116.6. The stock demonstrated strong performance with notable trading volume and turnover, outperforming its sector and trading above several moving averages, indicating a positive market position.

Par Drugs & Chemicals Ltd is experiencing notable buying activity, with its stock outperforming the Sensex in recent trading sessions. Over the past month, the stock has shown strong performance, indicating a potential shift in momentum despite a challenging year. It consistently trades above several moving averages.

Par Drugs & Chemicals Ltd experienced notable trading activity today, reaching the upper circuit limit with a high price of 111.05. The stock maintained this level throughout the session, with a trading volume of approximately 0.04283 lakh shares. It has outperformed its sector and shows positive momentum.

Par Drugs & Chemicals Ltd is experiencing heightened buying interest, with its stock price rising significantly today and showing strong gains over the past week and month. Despite a challenging year, recent performance suggests a positive shift in market sentiment, supported by favorable technical indicators and potential operational improvements.

As of 15-Sep, Par Drugs & Chemicals Ltd's stock price is 105.77, down 2.64%, and has underperformed its sector by 3.22%. Despite a modest weekly gain, its year-to-date decline is -46.82%, and long-term growth prospects are poor due to negative quarterly results and reliance on non-operating income.